The RNA Revolution - User Symposium
Cambridge, MA, USA
April 13, 2017
Le Meridien, Cambridge


We are pleased to invite you to join our third User Symposium in Cambridge. The aim of this event is to promote and facilitate scientific discussions and exchanges among existing and future RNAscope® users from various institutions who want single-molecule, single-cell detection of target expression in tissue.

This user symposium will feature presentations by scientists who have successfully applied RNAscope® technology in their research. Our invited speakers will show how this next generation RNA ISH enables and accelerates their research in the fields of cancer, gene therapy and neuroscience. They will present their scientific challenges and results, and will describe how they set up RNAscope® and BaseScope™ assays and established them as a core assay in their labs.


A technical presentation will close the session, addressing questions regarding how to produce quality results, optimize workflow and sample preparation as well as providing tips and tricks to perform RNAscope® assay successfully in your lab.  

Join us for this event and learn how RNAscope® technology, published in more than 700 publications and used in 2 clinical trials, can provide a unique perspective in target expression analysis and help in overcome your scientific challenges.


April 13, 2017 - 10:00 am to 5:00 pm

Le Meridien - 20th Sidney Street
Cambridge - Massachusetts - USA

Speakers and Presentations

  • Integration of in situ hybridization in the preclinical safety assessment of CAR T cells
    James B. Rottman, DVM, PhD, DACVP
    Senior Director, Translational Development, bluebird bio, Cambridge, MA
    Adjunct Associate Professor, Department of Biomedical Sciences, Tufts University Cummings School of Veterinary Medicine, North Grafton, MA

  • RNA In-situ Hybridization Technology for determining HPV status of oropharyngeal squamous cell carcinoma including discordant cases that are p16 positive by immunohistochemistry but HPV negative DNA in-situ hybridization: An important step forward in further defining a form of head and neck cancer that is changing the head and neck oncology landscape
    William H. Westra, M.D.
    Professor of Pathology, Oncology, and Otolaryngology/Head & Neck Surgery
    Associate Director, Surgical Pathology
    Director, The Head and Neck Pathology Consultation Service
    The Johns Hopkins Medical Institutions

  • Molecular localization studies to examine alterations in tumor microenvironment with EGFRvIII CAR T cell therapy
    Keith Mansfield, DVM, ACVP
    Director, Discovery and Investigative Pathology
    Novartis Institutes for Biomedical Research

  • RNAscope as a novel platform to interrogate the tumor microenvironment: Our experiences using the automated Ventana ULTRA platform
    Sandy Coetzee
    Manager, Oncology and Angiogenesis, Regeneron Pharmaceuticals, Inc.
  • Genetic Identification of Distinct Cell Populations in the Central Amygdala
    Joshua Kim
    PHD Candidate, 
    Riken-MIT Center for Neural Circuit Genetics, MIT.
  • Connecting the Dots, RNAscope Image Analysis with Visiopharm Software
    Stefan Hamann, PhD
    Senior Scientist, Research Technology, Biogen, Inc.
  • Characterizing Complex RNA and Protein Expression Patterns in the Tumor Microenvironment
    Adam Smith
    Sr. Applications Scientist / Strategic Accounts Manager, Indica Labs  

  • RNAScope into the clinic. Utilizing the technology as a Companion Diagnostic (CDx)
    Kevin Entwistle, Leica Biosystems
    Business Development Manager, Pharma Partnerships, Leica Biosystems
  • Tips for Getting Quality Data with RNAscope Assay
    Jacqueline Akech, Ph.D
    Senior Scientist and Technical Support Manager, Advanced Cell Diagnostics, Inc.

  • The Current State-of-the-Art Tissue Expression Analysis Platform for detection and quantification of target and biomarker mRNAs, splice variants and mutations in preclinical and clinical tissues
    Chris Bunker, Ph.D
    Vice President of Business Development, Advanced Cell Diagnostics, Inc.